Altimmune to Announce Third Quarter 2020 Financial Results on November 10
Altimmune, Inc. (Nasdaq: ALT) announced it will release its third quarter 2020 financial results on November 10, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announced it will release its third quarter 2020 financial results on November 10, 2020. A conference call for investors will follow at 8:30 a.m. ET on the same day, where management will discuss the financial results and provide a business update. The company, focused on developing intranasal vaccines and therapies, has a diverse pipeline including products for COVID-19, anthrax, and liver disease. For more details, investors can access the conference call via a webcast.
Positive
- Diverse pipeline including vaccines for COVID-19 and other diseases.
Negative
- None.
Details
News Market Reaction – ALT
The recorded move for ALT in the trading session of this news was +2.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.
Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update.
Conference Call Details
| Date: | Tuesday, November 10th |
| Time: | 8:30 am Eastern Time |
| Domestic: | 877-300-8521 |
| International: | 412-317-6026 |
| Conference ID: | 10149733 |
| Webcast: | http://public.viavid.com/index.php?id=142319 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
| Investor Contacts: | ||
| Will Brown | Ashley R. Robinson | |
| Chief Financial Officer | LifeSci Advisors, LLC | |
| Phone: 240-654-1450 | 617-430-7577 | |
| wbrown@altimmune.com | arr@lifesciadvisors.com | |
| Media Contacts: | ||
| Warren Rizzi | ||
| Sard Verbinnen & Co. | ||
| Phone: 212-687-8080 | ||
| altimmune-svc@sardverb.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.